🎥 Case study on video
When a pharma darling crashes: Novo Nordisk as a lesson in pipeline and competition risk (video in German):
1 · Why pharma is defensive
Demand for medicine barely tracks the economy — it's non-cyclical. Add demographics: an ageing population needs more treatment year after year. Large pharma earns from patent-protected, high-margin drugs and often pays dividends that have risen for decades. That's the defensive counterweight to cyclical hard assets.
2 · The large dividend payers
- Johnson & Johnson — Dividend King with 60+ years of uninterrupted increases and a AAA rating; broadly diversified (pharma + MedTech).
- AbbVie — strong payer, but must offset the Humira patent cliff with new drugs.
- Novartis & Roche (Switzerland) — European heavyweights with long payout histories.
- Pfizer, Merck — large US groups with solid dividends, valued differently depending on pipeline.
3 · The core risk: the patent cliff
When a key drug's patent expires, generics and biosimilars crush the price — revenue drops. That's the patent cliff, the central pharma risk.
4 · Pharma & healthcare ETFs
The cleanest way to spread patent risk: a healthcare or pharma ETF bundles many groups into one product — if one falls on a patent cliff, the others carry. For EU investors the same applies: choose an EU-tradable UCITS ETF on a healthcare or pharma index.
5 · The honest catch
- Pipeline/patent risk: the biggest unknown — one trial can turn the stock.
- Political price pressure: health systems push on drug prices (esp. US).
- Litigation risk: product liability and lawsuits can get expensive.
- Valuation: quality pharma is rarely cheap — buying weakness pays off.
6 · How pharma fits a portfolio
For me pharma is a defensive dividend block — a cashflow source that runs when cyclical hard assets weaken. I take it for stability and diversification, not as a return turbo, and weight breadth (a large diversified group or ETF) over a risky single bet on one pipeline.
7 · FAQ
Why are pharma stocks considered defensive?
Because demand for medicine barely depends on the economy and demographics provide a tailwind. Large groups have patent-protected, high-margin products and often pay dividends that have risen for decades.
Which pharma stocks pay good dividends?
Mostly the large diversified ones: J&J (Dividend King, 60+ years, AAA), AbbVie, Novartis, Roche, Pfizer, Merck. Yields roughly 2–5%.
What is the patent cliff?
The revenue drop when a key patent expires and generics/biosimilars cut the price. The company must have new drugs in its pipeline in time to replace it.
How do I invest in pharma broadly?
Through a healthcare/pharma ETF that spreads the single-stock patent-cliff risk. EU investors choose an EU-tradable UCITS ETF on a healthcare index.
What is the biggest risk with pharma stocks?
Pipeline and patent risk — plus political price pressure and litigation. Broad positioning and a full pipeline reduce it.